Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis Academic Article uri icon


MeSH Major

  • Hematologic Neoplasms
  • Janus Kinase 2
  • Mutation, Missense
  • Primary Myelofibrosis
  • Protein Kinase Inhibitors
  • Receptors, Thrombopoietin
  • Thrombocytosis


  • The discovery of JAK2 and MPL mutations in patients with myeloproliferative neoplasms (MPNs) provided important insight into the genetic basis of these disorders and led to the development of JAK2 kinase inhibitors for MPN therapy. Although recent studies have shown that JAK2 kinase inhibitors demonstrate efficacy in a JAK2V617F murine bone marrow transplantation model, the effects of JAK2 inhibitors on MPLW515L-mediated myeloproliferation have not been investigated. In this report, we describe the in vitro and in vivo effects of INCB16562, a small-molecule JAK2 inhibitor. INCB16562 inhibited proliferation and signaling in cell lines transformed by JAK2 and MPL mutations. Compared with vehicle treatment, INCB16562 treatment improved survival, normalized white blood cell counts and platelet counts, and markedly reduced extramedullary hematopoeisis and bone marrow fibrosis. We observed inhibition of STAT3 and STAT5 phosphorylation in vivo consistent with potent inhibition of JAK-STAT signaling. These data suggest JAK2 inhibitor therapy may be of value in the treatment of JAK2V617F-negative MPNs. However, we did not observe a decrease in the size of the malignant clone in the bone marrow of treated mice at the end of therapy, which suggests that JAK2 inhibitor therapy, by itself, was not curative in this MPN model.

publication date

  • April 8, 2010



  • Academic Article



  • eng

PubMed Central ID

  • PMC2854434

Digital Object Identifier (DOI)

  • 10.1182/blood-2009-04-218842

PubMed ID

  • 20154217

Additional Document Info

start page

  • 2919

end page

  • 27


  • 115


  • 14